Timolol/Dorzolamide

DEA Class;  Rx

Common Brand Names; Cosopt, Cosopt PF

Dorzolamide

• Ocular burning, stinging, discomfort (33%)
• Bitter taste (25%)
• Superficial punctate keratitis (10-15%)
• Ocular allergic reactions (10%)
• Blurred vision
• Ocular dryness
• Photophobia
• Ocular redness
• Tearing
• Stevens-Johnson syndrome
• Toxic epidermal necrolysis

Timolol

• Arrythmia
• Bradycardia
• Syncope
• Fatigue
• Headache
• Dyspnea
• Bronchospasm
• Chest pain
• Edema
• Paresthesia
• Nausea
• Rales
• Depression
• Decreased exercise tolerance
• Raynaud’s phenomenon

Dorzolamide (a sulfonamide) and, although administered topically, is absorbed systemically; same types of adverse reactions attributable to sulfonamides may occur with topical administration, including severe skin reactions; severe respiratory reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, reported following systemic or ophthalmic administration of timolol maleate

Hypersensitivity may occur; fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias; sensitization may recur when a sulfonamide is readministered irrespective of route of administration; if signs of serious reactions or hypersensitivity occur, discontinue use of this preparation

Bacterial keratitis associated with use of multiple-dose containers of topical ophthalmic products, inadvertently contaminated by patients who, in most cases, had concurrent corneal disease or disruption of ocular epithelial surface

Conjunctivitis reported with chronic administration (may resolve upon discontinuation of therapy)

Pregnancy Category: C

Lactation: Excreted in breast milk; not recommended